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Recently, the Healthcare Common Procedure Coding
System (HCPCS) coding committee for supplies [headed
up by Center for Medicare and Medicaid Services (CMS),
with private payer representatives] denied a request for a
unique HCPCS level II code for use of a novel bone
marrow biopsy system in the physician office setting
(POS). This code would in effect allow access/use of a
powered bone marrow biopsy system (brand name
OnControl) in this setting, where a significant number of
bone marrow biopsy procedures are performed. Hema-
tologists and oncologists perform the vast majority of these
types of procedures [1]. In randomized controlled trials this
new system has demonstrated significant reductions in
patient pain as well as significantly improving upon the
sample yield to more accurately assess a patient’s pathol-
ogy [2]. It also demonstrated the potential ability for a
patient to be able to better tolerate the pain of the biopsy
based on the visual analog scale (VAS) pain reduction seen
with the powered system [3]. Interestingly, 3 years prior to
this, CMS granted a unique code for the use of OnControl
in the hospital outpatient setting (HOPS), permitting the
full amount of this technology to be paid for. Why would
CMS pay additionally in one care setting but deny access in
another less expensive care setting (i.e., POS)? Before this
question is answered, we need a history of how this de-
termination was made.
CMS has a decision tree that it uses in determining
whether a product/service should be granted a unique
HCPCS code [4]. According to CMS representatives, this
request for a new code answered every one of the decision
tree points (including strong support from lymphoma pa-
tient advocacy groups for its use based on less pain and
improved outcomes) in the affirmative, save one: that this
technology belongs in a different code set, namely Com-
mon Procedure Terminology (CPT) level 1 coding [4]. A
unique CPT code had been applied for through the
American Medical Association (AMA) CPT back in 2011.
As part of the application process, the AMA CPT editorial
panel provides feedback to the applicant. The feedback
provided by medical specialties such as the American So-
ciety of Hematology (ASH) and the American Society of
Clinical Oncology (ASCO) stated that a CPT code already
existed (CPT 38221—bone marrow biopsy, needle or tro-
car) and that the AMA only established codes for services,
not technologies.
Currently CPT 38221 is paid by CMS at a national av-
erage rate of US$170.19 in the POS. This payment includes
the cost of a manual biopsy needle at an amount of
US$34.47—an inferior system to OnControl (based on
outcomes). Unfortunately, OnControl, has a list price of
US$140. Thus, if a clinician were to use OnControl in the
POS, they would likely lose money considering the other
costs that are incurred in this setting include physician
labor, other clinical labor, and other supplies associated
with this procedure. Therefore, the CMS payment of
US$170.19 effectively prohibits access of OnControl in
the POS. An alternative presented back in 2013 to ASCO
and ASH was to ‘‘re-price’’ CPT 38221 to include the costs
of OnControl. The problem with this option is that if CPT
38221 were ‘‘re-priced’’, it would incentivize clinicians to
use the manual needle system instead of OnControl and
‘‘pocket’’ the difference. ASCO representatives suggested
that a unique HCPCS level II code was a reasonable path to
follow. An application and presentation was made to CMS
on 28 May 2014, with the hope of establishing a unique
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HCPCS level II for the POS—to be used in conjunction
with CPT 38221. Unfortunately, CMS came back with the
determination that coding for this is the AMA’s responsi-
bility and not theirs. This effectively restricted access
(based on inadequate payment) to the use OnControl only
in the HOPS. What is so bad about having adequate pay-
ment for OnControl in the HOPS only?
In addressing this question, here are the issues with
having access to only one care setting (HOPS): first, it costs
the healthcare system significantly more to provide the
same procedure in the HOPS versus the POS. Even if
OnControl were to be paid additionally in the POS
[HOPS pays US$910 vs. POS at US$276
(US$170 ? US$106; assumes that OnControl would be
paid at the differential of its list price of US$140 less an
existing payment of US$34 for the manual biopsy system)],
POS would be significantly less costly. Second, not every
patient has access to HOPS, some only have access to the
POS. Third, it denies access to better medicine, as noted
above.
Why would CMS allow for access for this product
(based on coding and payment) in one care setting and not
another? Perhaps it has to do with more clinicians using
OnControl in the POS and its cost. Current estimates are
that approximately 43 % of all bone marrow biopsies are
performed in the POS. For CMS, this amounts to 61,000
bone marrow procedures performed in the POS for the
2012 fiscal year [1]. If a unique HCPCS level II code were
established (and assuming all of these procedures were now
performed using OnControl), it would amount to an ad-
ditional US$6.5 million to CMS. Considering CMS’s
budget is US$525 billion, this amounts to a 0.001 % in-
crease in their budget—in essence a rounding error. Per-
haps it has to do with the HCPCS coding committee setting
a precedent in establishing a unique HCPCS code. In the
presentation made to the committee on 28 May 2014, nu-
merous examples were provided where CMS had estab-
lished unique HCPCS codes that were the responsibility of
the AMA CPT panel [5]. What is it then? The only con-
clusion that this author can come up with is that CMS is
being penny wise but access and quality of care foolish. As
it relates to the US’s triple aim [improving health out-
comes, enhancing the patient experience (including ac-
cess), and controlling/reducing per capita costs of health
care] [6], the decision made by CMS has achieved a sin-
gular aim in ensuring care is less costly. However, im-
proving the experience and outcomes were apparently not
considered in this decision. CMS’s mission is as follows:
‘‘as an effective steward of public funds, CMS is com-
mitted to strengthening and modernizing the nation’s
health care system to provide access to high quality care
and improved health at lower cost’’. Again, the CMS ap-
parently did not consider its mission in this decision.
So whose responsibility should it be to ensure that
OnControl is accessible? It is this author’s contention that
the responsibility for establishing a HCPCS code and in
pricing it lies with the provider and payer communities,
since they are using and paying for it. CMS’s abdicating
this responsibility to others is avoiding a decision that they
should be making (and for which they have done so in the
past) and goes against their mission. Providers abdicating
this responsibility goes against ensuring their patients have
access to high-quality care. Thus, access to high-quality
care is held in limbo, stuck between two entities (payers
and providers) who are saying in effect, ‘‘This is your re-
sponsibility, not mine’’.
Is it also the author’s opinion that the Affordable Care
Act has resulted in decision makers (i.e., CMS, private
payers, hematology/oncology) becoming gun shy over any
kind of novel medical technology that even hints at an
increase in costs to the system. As noted in the Strategic
Goal #1 for strengthening healthcare located on the
Department of Health and Human Services website [7],
there is no mention anywhere in the objectives listed for
increasing costs, only in either keeping them the same (and
improving quality) or in lowering them and improving
quality. This is currently how value is being defined in the
USA. Based on the pressure that decision makers are under
to decrease costs, it is not surprising that this technology
was not granted an HCPCS code. Decision makers are thus
being encouraged to pay for value if it results in the same
or lower costs. This in itself is extremely concerning.
Ultimately, how does this affect the medical community?
This may just be the tip of the iceberg regarding CMS
determinations that follow. CMS has effectively drawn a
line in the sand stating it will not pay additionally for value.
This may result in other more costly care that provides for
better quality and access also being denied. Is this a
harbinger for things to come, and is this what the medical
community and patients want? Paying more for value
should also be part of the purchase equation in healthcare
as it commonly is in all other parts of commerce.
What is needed are alternative methodologies that define
value that is created. A way to do so is by examining the
downstream effects of a false negative finding with a
manual biopsy (i.e., for lymphoma). Below is what this
might look like.
For the cost differential:
• CMS currently pays US$170.19 (national average) for
CPT 38221 (bone marrow biopsy) when this procedure
is performed in the POS. Embedded in this amount is
US$34.47 allocated for manual bone marrow biopsy
supplies. As a side note, if the same procedure were
performed in the HOPS (approximately 57 % are
performed in this setting), the CMS reimbursement is
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currently US$826.26 (hospital) ? US$84.37
(physician) = US$910.63.
• Assume that CMS were to pay for OnControl in the
POS at the differential in supply costs between
OnControl and the manual biopsy needle costs
embedded in CPT 38221, or US$140-
US$34.47 = US$105.53. Thus, the total CMS reim-
bursement for use of the powered biopsy procedure
would be US$105.53 ? US$170.19 = US$275.72.
For outcomes:
• A significantly longer trephine biopsy length (i.e.,
biopsy sample) with OnControl [2]. In a recent study,
this increased trephine length was shown to increase the
positivity for lymphoma diagnosis by 25 % [65.5 %
positivity with a trephine length of 13–16 mm (OnCon-
trol finding) vs. 40.7 % positivity with a trephine
length of 9–12 mm (manual biopsy finding)] [2, 8]. In
other words, the samples provided with OnControl
reduced the number of false negative findings for
lymphoma diagnosis (false negative = a negative di-
agnostic finding when in fact lymphoma was present).
• For the cost analysis, let’s assume based on above that
one in four lymphomas will be missed based on a 25 %
differential in sensitivity between powered and manual
biopsy [8].
Based on current National Comprehensive Cancer Net-
work (NCCN) guidelines, a bone marrow biopsy may be
considered adequate if it is diagnostic for lymphoma [9]. If
the manual biopsy result is not diagnostic and lymphoma is
suspected, a patient will likely undergo follow-on contrast-
enhanced computed tomography (CT) scans of the neck/
chest/abdomen/pelvis (a total of three would be performed)
[9]. At current CMS rates and with multiple procedure
discounts, this results in an additional cost of US$744.60.
Using TreeAge Software, these costs were modeled out.
In the case where a false negative occurs on biopsy and the
clinician is smart enough to suspect lymphoma (and thus
order a CT scan), the costs of a false negative (which is a
portion of all biopsy costs) equals US$356.34 (manual
biopsy at US$170.19 ? contrast-enhanced CT scans of the
neck, chest, and abdomen/pelvis regions at
US$744.60 9 0.25) versus OnControl at US$275.72.
Thus, in the case of a false negative finding on manual
biopsy for lymphoma, OnControl costs less. Again, since
trephine sizes are smaller with a manual biopsy (and
smaller trephine sizes result in a higher proportion of false
negatives), these types of situations likely occur more
frequently than realized [8].
While new technologies that increase costs and improve
value are likely to be denied by payers prima facie, addi-
tional analysis such as the above may help. Until this
happens, newer, slightly more expensive technologies/ser-
vices will likely be denied.
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